Engemycin 10% Dd Solution For Injection
Revised: September 2010
AN: 00635/2008
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OFthe VETERINARY MEDICINAL PRODUCT FOLLOWED BY THE STRENGTH AND THE PHARMACEUTICAL FORM
Engemycin 10% DD, solution for injection
2. NAME AND PROPORTION OF EACH ACTIVE SUBSTANCE, AND OF ANY EXCIPIENT, IF KNOWLEDGE OF THE EXCIPIENT IS NEEDED FOR SAFETY REASONS
Active substance per ml:
Oxytetracycline (as hydrochloride) 100 mg
Antioxidant preservative per ml:
Sodium formaldehyde sulphoxylate 5 mg
For full list of excipients, see section 6.1
3. PHARMACEUTICAL FORM
Clear, yellow, aqueous solution for injection
4. CLINICAL PARTICULARS
4.1 Target species
Cattle, sheep, pigs, horses, dogs and cats
Indications for use, specifying the target species
For the treatment of infections caused by organisms sensitive to oxytetracycline in horses,cattle, sheep and pigs
In vitro, oxytetracycline is active against a range of both Gram-positive and Gram-negative micro organisms including:
Streptococcus spp., Staphylococcus spp., L. monocytogenes, P. haemolytica, H. parahaemolyticusand B. bronchisepticaand againstChlamydophila abortus, the causative organism of enzootic abortion in sheep
4.3 Contra-indications
Not to be administered to horses during concomitant therapy with corticosteroids.
Special warning for each target species
As with other tetracyclines, caution should be exercised in treating horses under stress.
Exercise caution in animals with hepatic or renal impairment.
4.5 Special precautions for use
i. Special precautions for use in animals
Not for intravenous administration in dogs or cats.
ii. Special precautions to be taken by the person administering the medicinal product to the animals
Take care to avoid accidental injection.
In case of contact with eyes or skin, wash immediately with plenty of water as irritation may occur.
Wash hands after use.
4.6 Adverse reactions (frequency and seriousness)
A transient swelling may be observed following intramuscular administration in horses and subcutaneous administration in dogs.
Photodermatitis may occur after treatment if exposure to intense sunlight occurs.
4.7 Use during pregnancy and lactation
The use of tetracyclines during the period of tooth and bone development, including late pregnancy, may lead to discolouration.
4.8 Interaction with other medicinal products and other forms of interaction
It is not recommended to administer bacteriostatic and bactericidal antibiotics concurrently.
4.9 Amounts to be administered and administration route
Can be administered at either a low dose rate for a 24 hour duration of activity or at a high dose rate for prolonged duration of activity.
24 hour dosage regime:
The recommended dosage rate is 3-10 mg/kg bodyweight (depending on age and species - see table) by intramuscular or intravenous injection in large animals and by subcutaneous or intramuscular injection in small animals.
The treatment may be repeated at 24 hour intervals up to 4 times (5 treatments in all).
Intravenous injections must be given slowly over a period of at least one minute.
Prolonged action dosage regime:
10 or 20 mg/kg bodyweight depending on age and species (see table) by intramuscular injection only, repeated once after 48-60 hours if required.
This dosage regime is not advised for use in horses, dogs or cats.
-
Animal
Weight kg
24 hour dosage
Prolonged action
Dose mg/kg
Volume ml
Dose mg/kg
Volume ml
Horse
Foal
Cow
Calf
Sow/boar
Pig
Sheep
Lamb
Dog
Cat
500
100
500
100
150
25
50
25
10
5
5
10
3
8
5
8
8
8
10
10
25
10
15
8
7.5
2
4
2
1
0.5
Not recom
Not recom
10
20
10
20
20
20
Not recom
Not recom
mended
mended
50
20
15
5
10
5
mended
mended
Prophylactic treatment of enzootic abortion in sheep:20 mg/kg administered about day 95-100 of gestation. A further treatment may be given 2-3 weeks later.
Before administration, clean the area of the injection site and swab with spirit. Repeat doses should be administered at different sites, and the sites massaged well after injection.
Maximum recommended dose at any one site: 20 ml for cattle, 10 ml for sheep and pigs.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Oxytetracyline has low toxicity, but is irritant. Overdosage should be avoided, particularly in horses. No recommended treatment.
4.11 Withdrawal periods for the various foodstuffs, including those for which the withdrawal period is zero
24 hour dose
-
Milk Cows
6 days
Cattle
35 days
Sheep
14 days
Pigs
14 days
Prolonged action dose
-
Milk Cows
6 days
Cattle
21 days
Sheep
14 days
Pigs
10 days
Not for use in horses intended for human consumption.
Not for use in sheep producing milk for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Oxytetracycline is a bacteriostatic antibiotic which has broad spectrum antibacterial activity against both gram-positive and gram-negative bacteria. After absorption it enters most tissues and body fluids, with the exception of CSF. It is excreted unchanged, mainly in urine.
ATC Vet code:QJ01AA06
Pharmacokinetics properties
From the site of injection the drug is effectively and rapidly absorbed with minimal irritation of the tissue thanks to the low viscosity of the solvent contained in the formulation, polyvinyl pyrrolidone (PVP).
Depending on the dose rate the duration of the action after a single administration is for 24 hours or prolonged to 48 – 60 hours.
After a standard dose of 3-8 mg oxytetracycline/kg BW to target animals, drug peak plasma concentrations were achieved in 1 - 4 hours and lasted to the level of 0.5 - 1.0 µg/mL, regarded as effective, in about 24 hours; by giving IM doses of 10 – 20 mg oxytetracycline/kg BW the action was prolonged and concentrations exceeding 0.5 – 1.0 µg/ml were maintained for about 48 hours.
The drug is widely distributed in the body with highest concentrations in liver, spleen, kidneys and the lungs. Oxytetracycline is moderately protein bound (about 50 %) and is excreted mainly unchanged by renal route, with same in the faecesand milk.
6. PHARMACEUTICAL PARTICULARS
List of excipients
Sodium formaldehyde sulphoxylate
Magnesium Oxide
Povidone K12
Ethonolamine
Water for injection
6.2 Major incompatibilities
Dilution with calcium salts is not recommended as this may lead to precipitation of crystals.
6.3 Shelf life, when necessary after reconstitution of the medicinal product or when the immediate packaging is opened for the first time
Shelf life: 2 years
Following withdrawal of the first dose, use the product within 28 days.
6.4 Special precautions for storage
Do not store above 25oC. Protect from light. Do not freeze.
Keep container in outer carton.
Nature and composition of immediate packaging
Vials of amber Type II (Ph Eur) glass or PET closed with halogenated butyl rubber stopper with aluminium overseal.
Multi-dose vials of 100 ml.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate
Any unused product or waste material should be disposed of in accordance with national requirements.
7. MARKETING AUTHORISATION HOLDER
Intervet International, BV, Boxmeer, Holland
Represented in the UK by:
IntervetUK Ltd.
Walton Manor
Walton
Milton Keynes
Buckinghamshire
MK7 7AJ
8. MARKETING AUTHORISATION Number
Vm06376/4007
9. Date of first AUTHORISation or date of renewal of the authorisation
11 December 2005
10. Date of Revision of text
September 2010